44 results
8-K
EX-99.1
SRZN
Surrozen Inc
8 May 24
Surrozen Provides First Quarter 2024 Financial Results and Business Update
4:12pm
potential for treatment of degenerative diseases and tissue injuries. Surrozen’s platform and proprietary technologies have the potential to overcome
8-K
EX-99.1
SRZN
Surrozen Inc
1 Apr 24
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
8:52am
and tissue injuries. Surrozen’s platform and proprietary technologies have the potential to overcome the limitations in pursuing the Wnt pathway
424B3
SRZN
Surrozen Inc
8 Nov 23
Prospectus supplement
4:27pm
may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against
8-K
EX-99.1
bli1jt
8 Nov 23
Surrozen Provides Third Quarter 2023 Financial Results
4:09pm
424B3
jf9n pkj90
9 Aug 23
Prospectus supplement
4:39pm
8-K
EX-99.1
vj7 xlbbejl0
9 Aug 23
Surrozen Provides Second Quarter 2023 Financial Results
4:16pm
424B3
3z9inz
10 May 23
Prospectus supplement
4:47pm
8-K
EX-99.1
duijhx3bt
10 May 23
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
4:14pm
424B3
h78znz x1rhol
7 Apr 23
Prospectus supplement
5:20pm
POS AM
93ghtd8j469dkerl7
31 Mar 23
Prospectus update (post-effective amendment)
9:09am
8-K
EX-99.1
a1oqllg g0nv0o
15 Nov 22
Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:12pm
8-K
EX-99.1
9w2wtazts5x9zop501y
11 Aug 22
Surrozen Reports Second Quarter 2022 Financial Results
12:43pm
8-K
EX-99.1
z3jal
11 May 22
Surrozen Reports First Quarter 2022 Financial Results
8:16am
424B3
nxs5i9o3axep3k3k
5 Apr 22
Prospectus supplement
4:43pm